You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The researchers found new molecular pathways of resistance, including hypoxia tolerance, protein folding, and mitochondria respiration.
The Israeli bioinformatics firm is also mulling an expansion into human genetics.
The company said it plans to use the funds to build out its annotated immune cell atlas and to expand its functional genomics capabilities.
An initial analysis suggests the Pfizer-BioNTech vaccine could reduce viral load, the Guardian reports.
A new study lends credence to the idea that pre-existing anti-cancer immunity depends heavily on patients' genetic background, according to one of the researchers.
News items for the week of Feb. 1, 2021.
The Israeli company, which specializes in informatics and AI for agricultural and livestock genomics, is trading on the Tel Aviv Stock Exchange.
Researchers profiled the transcriptomes of more than 500,000 single cells from human fetal skin and adult skin with atopic dermatitis and psoriasis.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.